Sepracor, Bayer Corp. deal

SEPR announced that its deal with Bayer Corp. for OTC R-ketoprofen has been terminated following the completion of clinical trials in which the drug's gastrointestinal side-effects were found to be slightly more severe than those of acetaminophen.

SEPR received $1 million in 1994 for development of the anti-inflammatory compound, and will receive $650,000 in 1995. Bayer recently received FDA approval for Actron, the racemic version of the product. ...